Genetically engineered mouse models of esophageal cancer

• Published in: Experimental cell research 2021-09, Vol.406 (2), p.112757-112757, Article 112757
• Main Authors: Mahmoudian, Reihaneh Alsadat, Farshchian, Moein, Abbaszadegan, Mohammad Reza
• Format: Article
• Language: English
• Subjects: 60 APPLIED LIFE SCIENCES; ANIMAL TISSUES; DIAGNOSIS; EAC; ESCC; ESOPHAGUS; GEMM; GENETICS; MICE; NEOPLASMS; PATHOGENESIS; PATIENTS; SIMULATION; Tissue-specific promoters
• ISSN: 0014-4827; 1090-2422
• DOI: 10.1016/j.yexcr.2021.112757

Esophageal cancer is the most common cause of cancer-related death worldwide with a diverse geographical distribution, poor prognosis, and diagnosis in advanced stages of the disease. Identification of the mechanisms involved in esophageal cancer development is evaluative to improve outcomes for patients. Genetically engineered mouse models (GEMMs) of cancer provide the physiologic, molecular, and histologic features of the human tumors to determine the pathogenesis and treatments for cancer, hence exhibiting a source of tremendous potential for oncology research. The advancement of cancer modeling in mice has improved to the extent that researchers can observe and manipulate the disease process in a specific manner. Despite the significant differences between mice and humans, mice can be great models for human oncology researches due to similarities between them at the molecular and physiological levels. Due to most of the existing esophageal cancer GEMMs do not propose an ideal system for pathogenesis of the disease, genetic risks, and microenvironment exposure, so identification of challenges in GEM modeling and well-developed technologies are required to obtain the most value for patients. In this review, we describe the biology of human and mouse, followed by the exciting esophageal cancer mouse models with a discussion of applicability and challenges of these models for generating new GEMMs in future studies.